BPCIA Complaint Against Proposed Rituxan® Biosimilar DRL_RI Filed
JD Supra Law
DECEMBER 14, 2023
On November 17, 2023, Genentech, Inc., Hoffmann-La Roche Inc., and Biogen Inc. (“Plaintiffs”) filed a BPCIA complaint (“Complaint”) against Dr. Reddy’s Laboratories, Inc., Dr. Reddy’s Laboratories SA (“DRL SA”), Dr. Reddy’s Laboratories Ltd., Fresenius Kabi USA, LLC, Fresenius Kabi Swissbiosim Gmbh, and Fresenius Kabi Deutschland GmbH (“Defendants”) in the District of New Jersey, requesting the Court to block Defendants’ “DRL_RI,” a proposed biosimilar of Plaintiffs’ Rituxan® (rituximab), from.
66 66
Let's personalize your content